John G Ullman & Associates Inc. Sells 4,300 Shares of Zimmer Biomet Holdings, Inc. $ZBH

John G Ullman & Associates Inc. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,850 shares of the medical equipment provider’s stock after selling 4,300 shares during the period. John G Ullman & Associates Inc.’s holdings in Zimmer Biomet were worth $2,358,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Garde Capital Inc. bought a new position in Zimmer Biomet in the first quarter worth approximately $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet in the first quarter worth approximately $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the first quarter worth approximately $30,000. Accent Capital Management LLC bought a new position in Zimmer Biomet in the first quarter worth approximately $35,000. Finally, Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 305 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.1%

ZBH stock opened at $102.00 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $20.21 billion, a PE ratio of 24.82, a P/E/G ratio of 2.35 and a beta of 0.67. The stock’s 50 day moving average is $101.74 and its 200-day moving average is $97.78. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the business posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.39% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent research reports. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. BTIG Research increased their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price on the stock. Finally, Evercore ISI dropped their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.